title: Decoy receptor-2 small interfering RNA (siRNA) strategy employing three different siRNA constructs in combination defeats adenovirus-transferred tumor necrosis factor-related apoptosis-inducing ligand resistance in lung cancer cells.
abstract: Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) selectively induces apoptosis in cancer cells but not in normal cells. However, studies have indicated that more than half of human tumors exhibit TRAIL resistance. Although the mechanism of TRAIL resistance is not understood, it represents a barrier to any TRAIL-mediated gene therapy approach. In addition, no correlation between TRAIL receptor (TRAIL-R) expression profile and TRAIL resistance has been demonstrated in cancer cells. In this study, three different lung cancer cell lines and three different primary cell cultures established from patients with lung cancer (two patients with squamous cell lung carcinoma and one with adenocarcinoma) were screened for sensitivity to adenoviral delivery of TRAIL. Whereas TRAIL-resistant primary lung cell cultures and the A549 lung cancer cell line exhibited high levels of surface decoy receptor-2 (DcR2/TRAIL-R4) expression, TRAIL-sensitive lung cancer cell lines (HBE and H411) failed to express it. A DcR2 short interfering RNA (siRNA) approach involving three different siRNA constructs in combination downregulated DcR2/TRAIL-R4 expression and sensitized lung cancer cells to TRAIL-induced apoptosis. Immunohistochemical staining of samples from 10 patients with lung carcinoma suggested that high-level DcR2/TRAIL-R4 expression is a common phenotype observed in patients with non-small cell lung carcinoma.
authors.affiliation: Human Gene Therapy Unit, Faculty of Medicine, Akdeniz University, 07070 Antalya, Turkey.
authors.forename: Cigdem
authors.initials: C
authors.lastname: Aydin
authors.forename: Ahter D
authors.initials: AD
authors.lastname: Sanlioglu
authors.forename: Bahri
authors.initials: B
authors.lastname: Karacay
authors.forename: Gulay
authors.initials: G
authors.lastname: Ozbilim
authors.forename: Levent
authors.initials: L
authors.lastname: Dertsiz
authors.forename: Omer
authors.initials: O
authors.lastname: Ozbudak
authors.forename: Cezmi A
authors.initials: CA
authors.lastname: Akdis
authors.forename: Salih
authors.initials: S
authors.lastname: Sanlioglu
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics / Q000378:metabolism / Q000628:therapy*; D000256:Adenoviridae; D017209:Apoptosis; D045744:Cell Line, Tumor; D015536:Down-Regulation / Q000235:genetics; D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics; D015316:Genetic Therapy; D006801:Humans; D008024:Ligands; D008175:Lung Neoplasms / Q000235:genetics / Q000378:metabolism / Q000628:therapy*; D018307:Neoplasms, Squamous Cell / Q000235:genetics / Q000378:metabolism / Q000628:therapy*; D034741:RNA, Small Interfering; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000378:metabolism; D053319:Tumor Necrosis Factor Decoy Receptors / Q000096:biosynthesis* / Q000235:genetics
chemical_list: D008024:Ligands; D034741:RNA, Small Interfering; D053221:TNF-Related Apoptosis-Inducing Ligand; C451501:TNFRSF10D protein, human; C505653:TNFSF10 protein, human; D053319:Tumor Necrosis Factor Decoy Receptors